UNASSIGNED: Objective: To study the molecular features of @entity652 ( @entity652 ) and discuss their values in differential diagnosis. Methods: @entity817 @entity8554 immunohistochemistry (IHC) using the mutation-specific VE1 monoclonal antibody and Sanger sequencing of @entity817 mutations were performed on 21 MAs, 16 epithelial-predominant @entity3969 (e-WT) and 20 the solid variant of @entity1358 (s- @entity35642 ) respectively. @entity986 protein was detected by IHC also. Fluorescence in situ hybridization (FISH) analyses using centromeric probes for chromosome 7 and 17 were performed on the three @entity703 in parallel. Results: Fourteen (14/21, 66.7%) of 21 @entity652 cases demonstrated diffuse, moderate to strong cytoplasmic @entity817 @entity8554 IHC staining and the @entity817 @entity8554 protein expression was detected in 2 (2/16) of 16 e-WT cases for the first time, whereas all s-PRCCs were negative (P<0.05). All cases (including 14 MAs and 2 e-WTs) with diffuse, moderate to strong cytoplasmic @entity817 @entity8554 IHC staining were confirmed to harbor @entity817 @entity8554 missense mutations using Sanger sequencing, and no @entity817 mutations were detected in cases with negative @entity817 @entity8554 protein expression. One case (1/21, 4.8%) showed trisomy of chromosome 7 alone, and another one (1/21, 4.8%) showed trisomy of chromosome 17 alone in 21 MAs. Two cases (2/16) of 16 e-WTs showed trisomy of chromosome 17 alone. In 20 s-PRCCs, trisomy of chromosomes 7 alone was reported in 2 cases (2/20), trisomy of chromosome 17 alone in 3 cases (3/20) and trisomy of chromosome 7 and 17 in 14 cases (14/20). The total positive rates of trisomy of chromosome 7 and/or 17 in MAs, e-WTs and s-PRCCs were 9.6% (2/21), 2/16 and 95.0% (19/20). @entity986 protein was positive in 81.0% (17/21) MAs, whereas the positive rates in e-WTs and s-PRCCs were 2/16 and 5.0% (1/20). Conclusions: Most MAs harbor @entity817 @entity8554 mutations, and MAs lack the gains of chromosome 7 and 17 that are characteristic of @entity1358 . These molecular features can be used to distinguish @entity652 from its mimics. @entity817 @entity8554 IHC using the mutation-specific VE1 monoclonal antibody provides an effective method in @entity817 @entity8554 mutations detection of @entity703 . @entity986 is overexpressed in @entity652 , and the finding suggests that the low proliferative rate of the @entity5 might be attributed to @entity817 @entity8554 -induced senescence mediated by @entity986 .

[Molecular features of XXXX and their values in differential diagnosis].

@entity35642 :: ('5546', 'Gene') :: ['PRCC'] @entity986 :: ('1029', 'Gene') :: ['p16'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['papillary renal cell carcinoma', 'papillary renal cell carcinomas'] @entity8554 :: ('p|SUB|V|600|E', 'ProteinMutation') :: ['V600E'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity3969 :: ('MESH:D009396', 'Disease') :: ['Wilms tumors'] @entity652 :: ('MESH:D000236', 'Disease') :: ['metanephric adenoma', 'MA'] @entity703 :: ('MESH:D007680', 'Disease') :: ['renal tumors']
@entity652 :: (MESH:D000236,Disease) :: ['metanephric adenoma']
